The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
The Expanding Role of the BCL6 Oncoprotein as a Cancer Therapeutic Target
Open accessAbstract
BCL6 was initially discovered as an oncogene in B-cell lymphomas, where it drives the malignant phenotype by repressing proliferation and DNA damage checkpoints and blocking B-cell terminal differentiation. BCL6 mediates its effects by binding to hundreds of target genes and then repressing these genes by recruiting several different chromatin-modifying corepressor complexes. Structural characterization of BCL6–corepressor complexes suggested that BCL6 might be a druggable target. Accordingly, a number of compounds have been designed to bind to BCL6 and block corepressor recruitment. These compounds, based on peptide or small-molecule scaffolds, can potently block BCL6 repression of target genes and kill lymphoma cells. In the case of diffuse large B-cell lymphomas (DLBCL), BCL6 inhibitors are equally effective in suppressing both the germinal center B-cell (GCB)- and the more aggressive activated B-cell (ABC)-DLBCL subtypes, both of which require BCL6 to maintain their survival. In addition, BCL6 is implicated in an expanding scope of hematologic and solid tumors. These include, but are not limited to, B-acute lymphoblastic leukemia, chronic myeloid leukemia, breast cancer, and non–small cell lung cancer. BCL6 inhibitors have been shown to exert potent effects against these tumor types. Moreover, mechanism-based combinations of BCL6 inhibitors with other agents have yielded synergistic and often quite dramatic activity. Hence, there is a compelling case to accelerate the development of BCL6-targeted therapies for translation to the clinical setting. Clin Cancer Res; 23(4); 885–93. ©2016 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Both corepressor proteins SMRT and N‐CoR exist in large protein complexes containing HDAC3
Li, J., Wang, J., Wang, J., Nawaz, Z., Liu, J. M., Qin, J., & Wong, J. (2000) · The EMBO Journal · doi:10.1093/emboj/19.16.4342 · Cited by 629
A core SMRT corepressor complex containing HDAC3 and TBL1, a WD40-repeat protein linked to deafness
Guenther, M. G., Lane, W. S., Fischle, W., Verdin, E., Lazar, M. A., & Shiekhattar, R. (2000) · Genes & Development · doi:10.1101/gad.14.9.1048 · Cited by 489
Cattoretti, G., Pasqualucci, L., Ballon, G., Tam, W., Nandula, S. V., Shen, Q., Mo, T., Murty, V. V., & Dalla-Favera, R. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.037 · Cited by 383
A Small-Molecule Inhibitor of BCL6 Kills DLBCL Cells In Vitro and In Vivo
Cerchietti, L. C., Ghetu, A. F., Zhu, X., Da Silva, G. F., Zhong, S., Matthews, M., Bunting, K. L., Polo, J. M., Farès, C., Arrowsmith, C. H., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.050 · Cited by 288
Self-citationRanuncolo, S. M., Polo, J. M., Dierov, J., Singer, M., Kuo, T., Greally, J., Green, R., Carroll, M., & Melnick, A. (2007) · Nature Immunology · doi:10.1038/ni1478 · Cited by 278
Self-citationBéguelin, W., Teater, M., Gearhart, M. D., Calvo Fernández, M. T., Goldstein, R. L., Cárdenas, M. G., Hatzi, K., Rosen, M., Shen, H., Corcoran, C. M., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.07.006 · Cited by 254
Self-citationArkin, M. R., & Whitty, A. (2009) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2009.05.125 · Cited by 190
Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma
Cardenas, M. G., Yu, W., Beguelin, W., Teater, M. R., Geng, H., Goldstein, R. L., Oswald, E., Hatzi, K., Yang, S.-N., Cohen, J., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85795 · Cited by 176 · cited 14×
“In fact, BCL6 is expressed in most activated B-cell (ABC)-type DLBCLs, albeit at lower levels (41, 48).”
BackgroundMethodInfluentialSelf-citationStructure of a BCOR Corepressor Peptide in Complex with the BCL6 BTB Domain Dimer
Ghetu, A. F., Corcoran, C. M., Cerchietti, L., Bardwell, V. J., Melnick, A., & Privé, G. G. (2008) · Molecular Cell · doi:10.1016/j.molcel.2007.12.026 · Cited by 168
Self-citationGreen, M. R., Vicente-Dueñas, C., Romero-Camarero, I., Long Liu, C., Dai, B., González-Herrero, I., García-Ramírez, I., Alonso-Escudero, E., Iqbal, J., Chan, W. C., et al. (2014) · Nature Communications · doi:10.1038/ncomms4904 · Cited by 88
Self-citation
Cited by
PROTACs: great opportunities for academia and industry
Sun, X., Gao, H., Yang, Y., He, M., Wu, Y., Song, Y., Tong, Y., & Rao, Y. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0101-6 · Cited by 613
Advances in Targeting ‘Undruggable’ transcription Factors With Small Molecules
Henley, M. J., & Koehler, A. N. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00199-0 · Cited by 409
Zhang, Z., Zhao, L., Zhou, X., Meng, X., & Zhou, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1098725 · Cited by 382
Targeted protein degradation: A promise for undruggable proteins
Samarasinghe, K. T. G., & Crews, C. M. (2021) · Cell Chemical Biology · doi:10.1016/j.chembiol.2021.04.011 · Cited by 271
McCoull, W., Cheung, T., Anderson, E., Barton, P., Burgess, J., Byth, K., Cao, Q., Castaldi, M. P., Chen, H., Chiarparin, E., et al. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.8b00698 · Cited by 139
Metadata
- Authors
- Cardenas, M. G., Oswald, E., Yu, W., Xue, F., MacKerell, A. D., & Melnick, A. M.
- Venue
- Clinical Cancer Research
- Published
- 2017-02-14
- Volume
- 23
- Issue
- 4
- Pages
- 885-893
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2554098092
- Cited by
- 180
- References
- 10
- FWCI
- 10.42
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Expanding Role of the BCL6 Oncoprotein as a Cancer Therapeutic Target. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-16-2071
- The paper
- Cardenas, M. G., Oswald, E., Yu, W., Xue, F., MacKerell, A. D., & Melnick, A. M. (2017). The Expanding Role of the BCL6 Oncoprotein as a Cancer Therapeutic Target. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-16-2071
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.